We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$650M
AUM Growth
+$95.3M
Cap. Flow
+$75.6M
Cap. Flow %
11.63%
Top 10 Hldgs %
57.73%
Holding
90
New
18
Increased
17
Reduced
23
Closed
25

Top Buys

Rank Stock Value
1
NPCE icon
Neuropace
NPCE
+$32.1M
2
FOCL
EDAP TMS S.A.
FOCL
+$16.9M
3
CCCC icon
C4 Therapeutics
CCCC
+$14.6M
4
NVCR icon
NovoCure
NVCR
+$14.3M
5
NEO icon
NeoGenomics
NEO
+$13.6M

Top Sells

Rank Stock Value
1
BCAB icon
BioAtla
BCAB
+$17.4M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$8.74M
3
KRYS icon
Krystal Biotech
KRYS
+$6.93M
4
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
+$5.31M
5
FLXN
Flexion Therapeutics, Inc.
FLXN
+$4.68M

Sector Composition

Rank Sector Weight
1 Healthcare 90.8%
2 Consumer Staples 2.41%
3 Financials 0.49%
4 Real Estate 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EIGR
51
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.82M 0.28%
7,117
– –
GLUE icon
52
Monte Rosa Therapeutics
GLUE
$1.3B
$1.7M 0.26%
+75,000
New +$1.53M
ATXS
53
DELISTED
Astria Therapeutics
ATXS
$1.64M 0.25%
129,167
– –
CMAX
54
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$1.53M 0.24%
3,963
– –
LYRA
55
DELISTED
LYRA THERAPEUTICS INC
LYRA
$1.47M 0.23%
3,662
-5,854
-62% -$2.67M
RNLX
56
DELISTED
Renalytix plc American Depositary Shares
RNLX
$1.46M 0.22%
47,300
-32,700
-41% -$979K
SPRY icon
57
ARS Pharmaceuticals
SPRY
$542M
$967K 0.15%
31,306
-65,950
-68% -$2.11M
DNTH icon
58
Dianthus Therapeutics
DNTH
$5.8B
$880K 0.14%
5,625
-625
-10% -$115K
TCRR
59
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$780K 0.12%
47,537
-94,600
-67% -$1.91M
EWTX icon
60
Edgewise Therapeutics
EWTX
$4.13B
$668K 0.1%
31,300
-68,700
-69% -$1.88M
NARI
61
DELISTED
Inari Medical, Inc. Common Stock
NARI
$574K 0.09%
6,150
-15,300
-71% -$1.48M
KDMN
62
DELISTED
Kadmon Holdings, Inc.
KDMN
$335K 0.05%
86,442
-250,000
-74% -$969K
RPTX
63
DELISTED
Repare Therapeutics
RPTX
$228K 0.04%
7,300
-126,024
-95% -$4.13M
ADVM
64
DELISTED
Adverum Biotechnologies
ADVM
– –
-9,999
Closed -$986K
CRDF icon
65
Cardiff Oncology
CRDF
$72.7M
– –
-42,684
Closed -$395K
DRIO icon
66
DarioHealth
DRIO
$69.2M
– –
-8,941
Closed -$3.44M
EXEL icon
67
Exelixis
EXEL
$13.8B
– –
-182,347
Closed -$4.12M
KYMR icon
68
Kymera Therapeutics
KYMR
$8.25B
– –
-28,116
Closed -$1.09M
MRK icon
69
Merck
MRK
$316B
– –
-31,551
Closed -$2.32M
IMDX
70
Insight Molecular Diagnostics
IMDX
$162M
– –
-14,850
Closed -$1.54M
PHG icon
71
Philips
PHG
$25.6B
– –
-75,279
Closed -$3.48M
RNAM
72
DELISTED
Avidity Biosciences
RNAM
– –
-109,130
Closed -$2.38M
SRRK icon
73
Scholar Rock
SRRK
$5.49B
– –
-26,101
Closed -$1.32M
STAA icon
74
STAAR Surgical
STAA
$1.21B
– –
-16,700
Closed -$1.76M
VRDN icon
75
Viridian Therapeutics
VRDN
$2.13B
– –
-67,685
Closed -$1.13M
1 2
3
4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Soleus Capital Management held 90 positions worth $650M, up 17% from $555M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Soleus Capital Management deployed $75.6M of net new capital in Q2 2021, opening 18 new positions and adding to 17 existing holdings. Its largest new stake was Neuropace: 1,384,387 shares worth $32.9M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was BioAtla, an estimated $17.4M trimmed.

  • Soleus Capital Management's largest Q2 2021 buy was Neuropace: 1,384,387 shares worth $32.9M.
  • Soleus Capital Management added most to EDAP TMS S.A. in Q2 2021, an estimated $16.9M increase.
  • Soleus Capital Management's biggest Q2 2021 reduction was BioAtla, cutting an estimated $17.4M.
  • Soleus Capital Management fully exited Flexion Therapeutics, Inc. in Q2 2021, selling an estimated $4.68M.
  • Soleus Capital Management's ten largest holdings make up 58% of its $650M portfolio in Q2 2021.
  • Soleus Capital Management opened 18 new positions and closed 25 in Q2 2021.
  • Soleus Capital Management's portfolio value rose 17% quarter-over-quarter to $650M.

Based on Soleus Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.